I'm not arguing that the AZ trials weren't messy, but the EMA also based their decision on antibody titers of the older cohorts (and on initial UK real use data

I'm not arguing that the AZ trials weren't messy, but the EMA also based their decision on antibody titers of the older cohorts (and on initial UK real use data if I'm not mistaken). > they are rigorous and extremely demanding about these subjects? While the older cohort is the one that suffers the most Covid causalities? MHRA thought it was a "risk" worth taking no? (because in the end it wasn't risky - maybe a slight smaller efficiency but that's it) > Maybe, just maybe Oh there's no maybe there, their trials were a mess, hence why the FDA asked for another trial.